Last updated: September 9, 2026
Alfentanil hydrochloride is a mature, off-patent injectable opioid used primarily for short-duration analgesia and anesthesia. Its commercial profile is defined by low market growth, limited supplier competition, controlled-substance compliance, hospital procurement pressure, and declining relevance relative to newer anesthetic protocols. Public sources do not report standalone global revenue for alfentanil hydrochloride, and the product is not a material growth asset for major pharmaceutical companies.
What is the current market status of alfentanil hydrochloride?
Alfentanil hydrochloride is an injectable synthetic opioid administered intravenously. The original branded product, Alfenta, was developed for rapid onset and short duration in anesthesia. It is substantially shorter-acting than fentanyl and has historically been used during induction, procedural anesthesia, and controlled intraoperative analgesia.
The active ingredient is generally supplied as an injection at a concentration of 500 micrograms per milliliter. The product is a Schedule II controlled substance in the United States, creating additional manufacturing, distribution, inventory, and recordkeeping requirements [1] [2].
The market has the following characteristics:
| Market factor |
Current effect |
| Product maturity |
Limits pricing power and innovation |
| Patent status |
Creates no meaningful composition-of-matter barrier |
| Route of administration |
Restricts use primarily to hospitals and procedural settings |
| Controlled-substance classification |
Raises compliance and supply-chain costs |
| Clinical substitutability |
Exposes alfentanil to fentanyl, remifentanil, and other anesthetics |
| Supplier economics |
Favors established injectable manufacturers |
| Demand profile |
Tracks surgical and procedural volumes rather than chronic treatment |
| Financial visibility |
Low, because companies generally do not report alfentanil sales separately |
Alfentanil does not have the commercial scale of fentanyl, remifentanil, morphine, or propofol. Its use is concentrated in anesthesia departments, operating rooms, intensive-care environments, and selected procedural settings.
When did alfentanil hydrochloride lose exclusivity?
Alfentanil hydrochloride lost meaningful market exclusivity decades ago. The original U.S. Alfenta product was approved in the 1980s, and any relevant composition-of-matter and primary product patents have expired. The product is therefore exposed to generic competition and therapeutic substitution.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Composition-of-matter patent |
Expired |
| Original product patents |
Expired or commercially irrelevant |
| Orange Book exclusivity |
No meaningful current exclusivity identified |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Not commercially relevant |
| Biosimilar exclusivity |
Not applicable |
| Generic competition |
Permitted where an approved supplier remains active |
Exact historical patent expiration dates are not commercially determinative because alfentanil has been available as an established generic injectable for many years. The current competitive question is supply continuity rather than patent exclusivity.
What patents protect alfentanil hydrochloride today?
No active patent estate is known to provide commercially meaningful protection for the alfentanil hydrochloride active ingredient or conventional injectable dosage form.
Potential historical patent categories included:
- The alfentanil chemical entity and related opioid compounds.
- Pharmaceutical compositions containing alfentanil.
- Injectable formulations.
- Anesthesia methods using alfentanil.
- Manufacturing and purification processes.
Those rights would generally have expired based on the age of the product. Any later patents covering narrow formulation, packaging, delivery, or process improvements would need to demonstrate a commercially meaningful distinction from standard alfentanil hydrochloride injection. Such rights would not restore broad market exclusivity for the active ingredient.
Are there formulation patents for alfentanil hydrochloride?
Conventional alfentanil hydrochloride injection is an old dosage form with limited patent differentiation. The main technical requirements are sterile manufacturing, concentration control, container compatibility, stability, and compliance with injectable-drug quality standards.
A supplier could theoretically pursue protection for:
- A novel extended-release formulation.
- A new noninjectable delivery system.
- A premixed infusion product.
- A specialized container or ready-to-administer presentation.
- A manufacturing process that produces a distinct quality or stability advantage.
No such product is known to have created a significant branded market position. The commercial opportunity would also be limited because alfentanil competes against established short-acting opioids and modern nonopioid anesthesia protocols.
What is the FDA regulatory status of alfentanil hydrochloride?
Alfentanil is an FDA-approved prescription opioid anesthetic. The original Alfenta labeling identifies intravenous administration for use in anesthesia and describes dosing requirements based on the anesthetic technique, patient characteristics, and concomitant drugs [1].
The product requires hospital-level controls because it is:
- A potent opioid.
- A parenteral product.
- A Schedule II controlled substance.
- Associated with respiratory depression, muscle rigidity, hypotension, and other opioid risks.
- Administered by trained clinicians with airway and monitoring capabilities.
FDA-regulated suppliers must comply with current good manufacturing practice requirements, controlled-substance quotas and records, sterile production standards, pharmacovigilance, and drug-shortage reporting obligations where applicable.
What is the Orange Book status of alfentanil hydrochloride?
The Orange Book is relevant to alfentanil because it identifies FDA-approved drug products and their therapeutic-equivalence status. The commercial value of any Orange Book listing is limited for an old injectable product with no active exclusivity.
For generic alfentanil hydrochloride injection, the key regulatory issues are:
- Whether an abbreviated new drug application remains approved.
- Whether the product is currently marketed.
- Whether the product is therapeutically equivalent to the reference listed drug.
- Whether supply is active or subject to discontinuation.
- Whether the listed dosage form and strength match hospital demand.
An Orange Book listing does not guarantee market availability. Products may remain approved while being discontinued, commercially inactive, or unavailable because of manufacturing constraints. FDA Drugs@FDA and the Orange Book should therefore be reviewed together when assessing current supplier status [3] [4].
How many companies manufacture alfentanil hydrochloride?
The number of active manufacturers varies by country and over time. U.S. supply has historically involved branded and generic injectable-drug companies, including suppliers associated with hospital pharmaceuticals. Manufacturers may change ownership, discontinue products, or retain regulatory approval without continuing active distribution.
The principal competitive groups are:
| Supplier group |
Competitive position |
| Original innovator |
Limited relevance after loss of exclusivity |
| Generic injectable manufacturers |
Primary source of U.S. hospital supply |
| Contract manufacturers |
May produce under another company’s label |
| European branded suppliers |
Relevant in selected national markets |
| Specialty hospital-drug companies |
May compete through shortages, packaging, or distribution |
The market is not broad enough to support extensive commercial segmentation. A company with a reliable sterile injectable platform can compete, but controlled-substance handling and low expected volumes can discourage entry.
Which companies are challenging alfentanil hydrochloride?
No material patent litigation or active Paragraph IV campaign is associated with alfentanil hydrochloride in the current market. The reason is economic: the relevant patents are old, the molecule is generic, and the remaining opportunity is too limited to justify major patent challenges.
Paragraph IV litigation historically would have been relevant to a generic seeking approval before patent expiry. That issue has largely disappeared because the original exclusivity period ended long ago. Current competition is more likely to involve:
- Abbreviated new drug application approval.
- Therapeutic-equivalence determinations.
- Manufacturing-site compliance.
- Drug-shortage response.
- Contracting with hospitals and group purchasing organizations.
- Controlled-substance distribution controls.
What patent litigation affects alfentanil hydrochloride?
No current high-value patent litigation is identified as a driver of the alfentanil hydrochloride market. The absence of litigation is itself commercially important. It means that market access is not constrained by a blocking patent, settlement agreement, or ongoing validity dispute.
Litigation risk remains possible in other areas, including:
- Product liability claims involving respiratory depression or dosing errors.
- Manufacturing-defect claims involving sterile injectables.
- Controlled-substance compliance actions.
- Regulatory enforcement involving distribution or recordkeeping.
- Commercial disputes over supply contracts.
These risks differ from patent risk and generally do not create exclusivity.
How does alfentanil compare with fentanyl and remifentanil?
Alfentanil competes most directly with fentanyl and remifentanil in procedural and intraoperative anesthesia.
| Attribute |
Alfentanil |
Fentanyl |
Remifentanil |
| Primary use |
Short-duration anesthesia analgesia |
Broad perioperative and acute analgesia |
Ultra-short-acting anesthesia |
| Onset |
Rapid |
Rapid |
Rapid |
| Duration |
Short |
Longer than alfentanil in many settings |
Very short |
| Administration |
Primarily IV |
IV, transdermal, transmucosal and other forms |
IV infusion |
| Patent position |
Expired |
Expired for core molecule; formulation patents may vary |
Expired core molecule; formulation and delivery rights may vary |
| Market scale |
Niche |
Large |
Specialty anesthesia market |
| Main commercial advantage |
Rapid titration and short duration |
Broad clinical familiarity and product availability |
Predictable offset and infusion control |
| Main constraint |
Limited market size and supplier availability |
Opioid safety and abuse controls |
Higher acquisition cost and infusion complexity |
Fentanyl has the broadest commercial footprint. Remifentanil competes where rapid recovery and precise infusion control justify its cost. Alfentanil occupies a narrower position and is more exposed to substitution.
What is the financial trajectory for alfentanil hydrochloride?
Alfentanil hydrochloride is a mature, low-growth pharmaceutical product. Its financial trajectory is more likely to be flat or declining in nominal terms than expanding.
Revenue drivers
Demand is tied to:
- Surgical procedure volumes.
- Hospital anesthesia protocols.
- Availability of competing opioids.
- Generic supplier participation.
- Drug shortages affecting alternatives.
- Hospital purchasing contracts.
- Regional clinical practice.
There is no publicly reported standalone revenue figure for alfentanil hydrochloride from major manufacturers. Companies generally include the product, if reported at all, within broader hospital injectable, anesthesia, or generic portfolios.
Margin profile
Gross margins can be affected by the following factors:
- Small production runs.
- Sterile injectable manufacturing costs.
- Controlled-substance security and compliance.
- Regulatory maintenance costs.
- Low volume per customer.
- Hospital purchasing discounts.
- Contract-manufacturing economics.
- Product shortages and expedited logistics.
A generic supplier may maintain the product for portfolio completeness or shortage resilience even when absolute revenue is modest. A supplier with existing sterile injectable capacity can achieve better economics than a new entrant because fixed manufacturing and regulatory costs are already allocated across a broader product portfolio.
Revenue exposure for pharmaceutical companies
Alfentanil is unlikely to represent material revenue exposure for diversified pharmaceutical companies. The principal financial risk is operational rather than strategic:
- A discontinuation can create hospital supply disruption.
- A quality event can remove a limited supplier from the market.
- A manufacturing delay can shift demand temporarily to competitors.
- A shortage can raise spot prices but usually does not create durable value.
- Demand can decline when hospitals adopt remifentanil, fentanyl, multimodal anesthesia, or nonopioid protocols.
What generic launch scenarios exist for alfentanil hydrochloride?
Three commercial scenarios are most relevant.
Base case: stable niche supply
Existing manufacturers continue supplying hospitals with limited volume growth. Pricing remains competitive, and the product remains available as a standard injectable anesthetic.
Downside case: supplier withdrawal
One or more manufacturers discontinue the product because of low demand, sterile manufacturing costs, or compliance burdens. Availability becomes intermittent, and hospitals substitute fentanyl, remifentanil, or another opioid.
Upside case: shortage-driven demand
A shortage of competing anesthetic opioids temporarily increases alfentanil orders. This can improve short-term volumes and pricing, but the effect is unlikely to create durable market expansion.
A new generic entrant would face a modest addressable market, regulatory and manufacturing costs, controlled-substance obligations, and established substitutes. The strongest entry rationale would be a portfolio strategy rather than a standalone alfentanil investment.
What geographic markets are relevant?
Alfentanil availability is uneven across jurisdictions. The product has historically been marketed in the United States and Europe under different regulatory and commercial arrangements, including the Rapifen brand in certain markets.
Geographic performance depends on:
- National authorization status.
- Hospital procurement systems.
- Local generic competition.
- Controlled-substance rules.
- Reimbursement and tender pricing.
- Availability of fentanyl and remifentanil.
- National drug-shortage conditions.
The United States remains relevant because of its large hospital market and regulated generic-drug system. European markets may have stronger dependence on national tenders, local distributors, and branded legacy products. Market entry in either region requires country-specific regulatory and controlled-substance compliance.
How strong is the alfentanil hydrochloride patent estate?
The patent estate is weak from an exclusivity perspective and moderate only as a historical technical record. There is no apparent active composition-of-matter barrier, no meaningful Orange Book exclusivity, and no material patent litigation blocking generic supply.
The remaining barriers are operational:
- Sterile injectable manufacturing.
- Controlled-substance authorization.
- FDA or national marketing authorization.
- Hospital contracting.
- Product reliability.
- Pharmacovigilance and quality systems.
For investors and licensing teams, alfentanil should be valued as an established hospital generic, not as a patent-protected pharmaceutical asset.
Key Takeaways
- Alfentanil hydrochloride is an old, off-patent injectable opioid used mainly in anesthesia.
- The original product exclusivity period expired decades ago.
- No active patent estate appears to provide broad commercial protection.
- No material current Paragraph IV or patent-litigation issue drives the market.
- The FDA regulatory status is established, but active commercial availability must be distinguished from historical approval.
- Market demand is niche and tied to surgery, anesthesia practice, and supply conditions.
- Fentanyl and remifentanil are the principal competitive alternatives.
- Public companies do not generally disclose standalone alfentanil revenue.
- Financial performance is likely stable to declining, with temporary upside during competitor shortages.
- The principal barriers are sterile manufacturing, controlled-substance compliance, and hospital procurement, not intellectual property.
FAQs
Is alfentanil hydrochloride still commercially available?
Availability varies by country, manufacturer, and time period. FDA approval or historical listing does not establish continuous commercial distribution.
Is alfentanil hydrochloride a controlled substance?
Yes. In the United States, alfentanil is regulated as a Schedule II opioid, which imposes heightened manufacturing, distribution, storage, and recordkeeping requirements [2].
Does alfentanil hydrochloride have biosimilar competition?
No. Biosimilar pathways apply to biological products. Alfentanil hydrochloride is a chemically synthesized small-molecule drug and competes through generic-drug pathways.
Can a company obtain new patents on alfentanil hydrochloride?
A company could seek patents on a genuinely novel formulation, delivery system, manufacturing process, or method of use. Such patents would not automatically provide broad protection for conventional alfentanil hydrochloride injection.
Is alfentanil hydrochloride an attractive licensing opportunity?
The product is generally more suitable for a hospital-generic portfolio or supply-continuity strategy than for a standalone licensing investment. Its limited market size, mature patent position, and therapeutic substitutes constrain upside.
References
- U.S. Food and Drug Administration. (n.d.). Alfenta (alfentanil hydrochloride) injection prescribing information. FDA.
- U.S. Drug Enforcement Administration. (n.d.). Controlled substances act. U.S. Department of Justice.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
